Squarepoint’s Unity Biotechnology UBX Stock Holding History

Squarepoint’s Portfolio UBX Stock Details UBX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-27,500	Closed	-$28.6K	–	5081
2025 Q1	$28.6K	Buy	+27,500	New	+$49.7K	﹤0.01%	4414

Other funds holding UBX

AVM

Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

FFVM

Founders Fund V Management San Francisco, California $2.16M AUM 77.37% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Squarepoint's UBX Position: Q1 2025 in Review

Squarepoint sold out of Unity Biotechnology (UBX) in Q1 2025, closing a stake of 18,332 shares — an estimated $33.1K sold.

Squarepoint first reported a position in UBX in Q3 2019 and held it in 9 quarters. The position peaked at $395K in Q4 2019. 40 funds tracked by Wall St. Rank hold UBX as of Q1 2025.

Squarepoint reported no remaining Unity Biotechnology position as of Q1 2025 after selling out during the quarter.
Squarepoint sold 18,332 Unity Biotechnology shares in Q1 2025, an estimated $33.1K.
Squarepoint first reported a position in Unity Biotechnology in Q3 2019 and held it in 9 quarters.
Squarepoint's Unity Biotechnology position peaked at $395K in Q4 2019.
40 funds tracked by Wall St. Rank held Unity Biotechnology as of Q1 2025.

Based on Squarepoint's 13F filing for Q1 2025, filed 15 May 2025.